Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

3.020 +0.020 (+0.67%)
Official Closing Price Updated: 4:15 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET 
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 ↗
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 ↗
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in May
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March ↗
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
News headline image
Crude Oil Down 1%; Charles Schwab Sales Top Estimates ↗
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? ↗
Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution. 
Via Benzinga
News headline image
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug ↗
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
News headline image
Why Is Mobile Global Esports (MGAM) Stock Down 18% Today? ↗
Mobile Global Esports stock is falling on Monday after the company revealed that shares of MGAM will be delisted later this week. 
Via InvestorPlace
News headline image
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? ↗
Neumora Therapeutics stock is falling on Monday as investors in NMRA shares react to a clinical trial being put on hold by the FDA. 
Via InvestorPlace
News headline image
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
Via InvestorPlace
News headline image
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
News headline image
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday ↗
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 ↗
NMRA stock results show that Neumora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
From Neumora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.